CSL shares (ASX: CSL) have given holders something to smile about over the past month, off the back of a hugely difficult year in public markets. The CSL share price has clawed back 27.66% from early June lows near A$90, with shares now trading at A$117.75, still 51.14% lower on a trailing 12 month basis.
Having stair stepped lower incrementally on the chart (as you can see below), markets are now reassessing whether the biotechnology giant’s recent profit downgrade and US$5 billion impairment mark a clearing event or signal deeper structural challenges ahead.
Is the bottom finally in at CSL?
The recovery in CSL shares follows one of the most turbulent periods in the company’s history, with the latest pullback coming courtesy of a 16% single session drop early May, after management slashed fiscal 2026 profit guidance to approximately US$3.1 billion, down from prior expectations of 4-7% growth and below the previous year’s US$3.3 billion result. The guidance cut, coupled with flagged impairments of around US$5 billion across fiscal years 2026-27 tied largely to the underperforming Vifor nephrology acquisition, sent CSL shares to their lowest levels since 2016.
Yet the subsequent rebound has been equally striking. After briefly touching the A$90 level in early June, shares have climbed steadily through the A$110s and are now testing the A$120 threshold, a potential resistance zone that provided support through May before the downturn.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The 27.66% gain over the past month suggests that at least some view the dramatic sell-off as an overreaction, with the combination of depressed sentiment, a reset earnings base, and CSL’s dominant position in plasma-derived therapies creating what value-oriented buyers see as a compelling entry point.
Behind the selloff
The core of CSL’s troubles stems in large part from the troubled Vifor acquisition and weakness in its Seqirus influenza vaccines division.
The US$6.5 billion purchase of Swiss pharmaceutical group Vifor in 2022 has consistently underperformed initial expectations, with integration challenges and regulatory headwinds preventing the nephrology assets from earning their cost of capital. The substantial write-downs now being taken across fiscal 2026-27 represent management’s acknowledgement that the deal thesis was overly optimistic, a concession that has damaged investor trust and raised questions about the company’s capital allocation discipline.
Meanwhile, Seqirus (representing ~14% of group revenue) has emerged as a persistent source of volatility despite its relatively modest size. Management has repeatedly flagged weaker US influenza vaccination rates for fiscal years 2025-26, guiding to a 6-8% decline in the 2025/26 US flu vaccine market value. The company has also paused or re-sequenced plans to demerge Seqirus, which had originally been targeted for June 2026, citing softer market conditions and demand uncertainty.
Against this backdrop of disappointments, however, stands CSL’s core plasma franchise. Fiscal years 2026-27 is thought to mark the period when CSL’s margin rebuild thesis starts to show concrete progress.
Plasma collection volumes have recovered from COVID-era lows, higher-yielding centres and improved donor management are supporting unit cost reductions, and pricing power in immunoglobulins and specialty plasma products remains solid. Recent half-year results showed group revenue up mid-single digits, with plasma and Vifor performing better than Seqirus, and immunoglobulin products like Hizentra delivering double-digit growth.
CSL has backed this recovery narrative with significant capital commitments, announcing a multi-year plasma manufacturing expansion adding roughly US$1.5 billion over five years to an already substantial programme exceeding US$3 billion since 2018. The scale of this investment is aimed at supporting volume growth and improving efficiency across the global network, underpinning the thesis that CSL is transitioning from a period of heavy investment to one of harvesting, with operating leverage to come.
View from the street
The analyst community remains broadly constructive despite recent setbacks. Consensus ratings cluster around Buy, with an average 12-month price target near A$140, implying material upside from current levels around A$118. Some local brokers have shifted to Hold or Neutral at prices near A$115-120, effectively marking that zone as fair value pending clearer evidence of margin recovery.
What next?
For bulls, management has taken large impairments, reset guidance to beatable levels, and cleared the decks for a period of more predictable performance. The core plasma franchise remains structurally attractive, with demographic tailwinds supporting demand for immunoglobulins and other plasma-derived therapies over the long term. The heavy capex programme, while increasing execution risk, also positions CSL to capture volume growth as manufacturing capacity comes online. And at current valuations, the stock trades near multi-year lows relative to its own history, even as the fundamental business continues to generate substantial cash flow.
Bears, however, see a company that has shifted from a perennial quality compounder to a more complex, conglomerate-style group with moving parts that are harder to model and multiple sources of earnings volatility. They argue that despite the capex, CSL is now in a structurally lower growth bracket than in the past decade, with more cyclical and regulatory risk in both plasma and vaccines.
The next test for CSL shares will be whether the company can deliver on the margin rebuild thesis in upcoming results and whether Seqirus stabilises as the northern hemisphere moves into the next flu season. Until then, the A$120-125 zone is likely to remain a battleground between bulls betting on a multi-year recovery and bears viewing the recent rally as a technical bounce in a longer-term downtrend.
